TrialHematological oncology2023

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.

Carmelo Carlo-Stella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.